1. Show article details.

    Avanafil Clinical Data to Be Presented at European Association of Urology

    Market Wire – 7:00 AM ET 04/11/2014

    04/11/14 -- VIVUS (VVUS) today announced that a poster describing results of a clinical study examining onset of action of avanafil will be presented during the 29th Annual European Association of Urology Congress at Stockholmsmässan in Stockholm, Sweden. About the Study Authors: Hartmut Porst, Ian Eardley, Dimitrios Hatzichristou, Craig Peterson, Winnie Shih.

  2. Show article details.

    Three VIVUS Directors Not Standing for Re-Election

    Market Wire – 5:00 PM ET 04/08/2014

    04/08/14 -- VIVUS, Inc. (VVUS) today announced that J. Martin Carroll, Mark B. Logan and Robert N. Wilson have decided not to stand for re-election when their terms expire at the Annual Meeting of Stockholders, to be held on June 20, 2014. "We are grateful to Marty, Mark and Bob for their tireless efforts on behalf of VIVUS," said Michael J. Astrue, chairman of VIVUS.

  3. Show article details.

    US STOCKS-Wall St dips as investors wary before jobs data

    Reuters – 5:14 PM ET 04/03/2014

    * Biotech, momentum stocks slide, pulling Nasdaq down. * Anadarko Petroleum (APC) settles pollution clean-up claims; stock soars. * Wider U.S. trade deficit to weigh on first-quarter GDP. * Dow flat; S&P 500 off 0.1 pct; Nasdaq down 0.9 pct. By Caroline Valetkevitch.

  4. Show article details.

    US STOCKS-Wall St slips as biotech, momentum stocks lead decline

    Reuters – 2:32 PM ET 04/03/2014

    * Biotech, momentum stocks lead Nasdaq down 1 pct. * Wider U.S. trade deficit to weigh on first-quarter GDP. * Dow off 0.2 pct; S&P 500 off 0.2 pct; Nasdaq down 1.1 pct. By Angela Moon. U.S. stocks fell on Thursday afternoon, led by a sharp drop in biotech and momentum stocks, including Facebook (FB), Tesla and Netflix.

  5. Show article details.

    US STOCKS-Wall St little changed after claims, ISM data

    Reuters – 10:54 AM ET 04/03/2014

    * Initial claims rise more than expected. * ISM rises, but shy of expectations. * Google (GOOG) dividend takes effect. * Indexes off: Dow 0.07 pct, S&P 0.11 pct, Nasdaq 0.37 pct. By Chuck Mikolajczak.

  6. Show article details.

    US STOCKS-Wall St to open flat after claims data; ISM on tap

    Reuters – 8:51 AM ET 04/03/2014

    * Initial claims rise more than expected. * ISM services due. * ECB keeps interest rates unchanged. * Google (GOOG) dividend to take effect Thursday. * Futures: Dow 7 pts, S&P 0.25 pt, Nasdaq off 1.5 pts. By Chuck Mikolajczak.

  7. Show article details.

    Wall Street dips as investors wary before jobs data

    Reuters – 7:39 AM ET 04/03/2014

    U.S. stocks slipped on Thursday, as investors turned cautious ahead of Friday's monthly jobs report, while a drop in biotech and momentum shares dragged the Nasdaq down nearly 1 percent. The Dow ended down just a fraction of a point, within about 4 points of its record closing high of 16,576.66 set on December 31.

  8. Show article details.

    US STOCKS-Futures little changed ahead of initial claims data

    Reuters – 7:36 AM ET 04/03/2014

    * Initial claims, ISM services due. * ECB rate decision on tap. * Google (GOOG) dividend to take effect Thursday. * Futures up: Dow 22 pts, S&P 2 pts, Nasdaq 3.75 pts. By Chuck Mikolajczak. U.S. stock index futures were little changed on Thursday, after the S&P 500 set a record for a second straight day, ahead of data on the labor market and services sector.

  9. Show article details.

    VIVUS to Present at Upcoming Investor Conference

    Market Wire – 7:00 AM ET 04/03/2014

    04/03/14 -- VIVUS, Inc. (VVUS) today announced that management will present an overview of the company at the following investor conference: 13th Annual Needham Healthcare ConferenceApril 8, 2014, 3:40pm EDTThe Westin Grand Central Hotel, New York. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.

  10. Show article details.

    Newly Published Review Article Summarizes Cardiovascular Benefit-Risk Profile of Qsymia

    Market Wire – 7:00 AM ET 03/25/2014

    03/25/14 -- VIVUS, Inc. (VVUS) today announced that a review article has been published online in the Journal of Hypertension, the official publication of the International Society of Hypertension and the European Society of Hypertension, summarizing the cardiovascular benefit-risk profile of Qsymia® capsules CIV.

  11. Show article details.

    Pre-Market Pulse - Health Care Sector Stocks -- Research on Exelixis, StemCells, Dendreon, and Vivus

    PR Newswire – 10:46 AM ET 03/24/2014

    LONDON, March 24, 2014 On Friday, March 20, 2014, the NASDAQ Composite ended at 4,276.79, down 0.98%, the Dow Jones Industrial Average fell by 0.17% to close at 16,302.77, and the S&P 500 finished at 1,866.52, down 0.29%. Four out of ten sectors ended the session in negative. http://Investor-Edge.com   SOURCE Investor-Edge.

  12. Show article details.

    Shari Belafonte Partners With VIVUS to Encourage Adults to Speak With Their Doctors About Losing Weight and Treatment Options Now Available

    Market Wire – 7:00 AM ET 03/19/2014

    03/19/14 -- VIVUS, Inc. (VVUS) today announced that Shari Belafonte is teaming up with the company to educate American adults about seeking medical treatment for chronic weight management when diet and physical activity alone have not been successful.

  13. Show article details.

    VIVUS Reports Fourth Quarter and Year-End 2013 Financial Results

    GlobeNewswire – 4:00 PM ET 02/24/2014

    VIVUS, Inc. (VVUS), a biopharmaceutical company commercializing Qsymia® capsules CIV for the treatment of obesity, today provided a business update and reported its financial results for the fourth quarter and year ended December 31, 2013.

  14. Show article details.

    VIVUS Announces Date of Fourth Quarter and Year End 2013 Financial Results and Conference Call

    GlobeNewswire – 7:00 AM ET 02/19/2014

    VIVUS, Inc. (VVUS) today announced that it will report financial results for the fourth quarter and year ended December 31, 2013 after the NASDAQ Market closes on Monday, February 24, 2014. Date: February 24, 2014 Time: 1:30 PM PT. Listen via Internet: http://ir.vivus.com/ Schedule this webcast into MS-Outlook calendar: http://apps.shareholder.com/PNWOutlook/t.aspx?m=63248&k=3AE857B1.

  15. Show article details.

    Investor seeks board seats at Ariad Pharmaceuticals -sources

    Reuters – 4:40 PM ET 02/06/2014

    A large shareholder is seeking to get at least two board seats at Ariad Pharmaceuticals Inc (ARIA), the drugmaker grappling with safety concerns involving its leukemia drug Iclusig, according to people familiar with the matter.

  16. Show article details.

    VIVUS and Auxilium Announce FDA Acceptance of Supplemental Filing Seeking an Update of Prescribing Information for STENDRA (avanafil)

    PR Newswire – 7:05 AM ET 01/21/2014

    MOUNTAIN VIEW, Calif. and CHESTERBROOK, Pa., Jan. 21, 2014VIVUS, Inc. (VVUS) and Auxilium Pharmaceuticals, Inc. (AUXL) today announced that the U.S. Food and Drug Administration has accepted a supplemental application that proposes to revise the STENDRA™ prescribing information with efficacy and safety information from Study TA-501, entitled "A Randomized, Double-Blind, Placebo-Controlled Evaluation of Ava...

  17. Show article details.

    VIVUS and Auxilium Announce FDA Acceptance of Supplemental Filing Seeking an Update of Prescribing Information for STENDRA (Avanafil)

    GlobeNewswire – 7:00 AM ET 01/21/2014

    MOUNTAIN VIEW, Calif. and CHESTERBROOK, Pa., Jan. 21, 2014 -- VIVUS, Inc. (VVUS) and Auxilium Pharmaceuticals, Inc. (AUXL) today announced that the U.S. Food and Drug Administration has accepted a supplemental application that proposes to revise the STENDRA™ prescribing information with efficacy and safety information from Study TA-501, entitled "A Randomized, Double-Blind, Placebo-Controlled Evaluation of...

  18. Show article details.

    VIVUS Collaborates With Aetna to Test First Comprehensive Weight Management Program Integrating Weight Loss Medication

    GlobeNewswire – 7:00 AM ET 01/14/2014

    VIVUS, Inc. (VVUS), today announced that it has joined with Aetna (AET), one of the nation's leading diversified health care benefits companies, to integrate Qsymia® capsules CIV into a pilot program designed to evaluate the benefits of prescription medication combined with lifestyle support for weight loss.

  19. Show article details.

    VIVUS to Present at Upcoming Investor Conference

    GlobeNewswire – 7:00 AM ET 01/13/2014

    VIVUS, Inc. (VVUS) today announced that management will present an overview of the company at the following investment conference: A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com. About VIVUS (VVUS) VIVUS (VVUS) is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes an...

  20. Show article details.

    VIVUS Announces License and Commercialization Agreement With Sanofi for Avanafil in Africa, Middle East, Turkey and CIS/Russia

    GlobeNewswire – 7:00 AM ET 12/12/2013

    VIVUS, Inc. (VVUS) today announced that it has entered into a License and Commercialization Agreement with Sanofi to commercialize avanafil on an exclusive basis in Africa, the Middle East, Turkey, and the Commonwealth of Independent States including Russia. Under the terms of the agreement, VIVUS (VVUS) is eligible to receive up to $61 million in upfront payments, regulatory and sales milestones.

Page:

Today's and Upcoming Events

  • May
    6

    VVUS to announce Q1 earnings Before Market (Unconfirmed)

  • Jun
    20

    Shareholders Meeting

Past Events (last 90 days)

  • Feb
    24

    VVUS Earnings Conference Call at 4:30 PM Listen

Data provided by Wall Street Horizon, Inc. © 2014

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.